Effect of Photobiomodulation to Reduce Post-operative Pain After Endodontic Surgery

Pain Clinical Trial

Official title:

Effect of Photobiomodulation to Reduce Post-operative Pain After Endodontic Surgery: a Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05935306
• Other study ID #: Pain after endodontic surgery
• Status: Not yet recruiting
• Phase: N/A
• Start date: May 30, 2024
• Est. completion date: November 1, 2024

Study information

• Verified date: May 2023
• Source: University of Nove de Julho
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study will be to evaluate if photobiomodulation (FBM) can reduce postoperative pain in patients who will undergo endodontic surgery. For this randomized, controlled and double-blind clinical study, 34 patients without comorbidities who need endodontic surgery in the upper jaw (15 to 25 teeth) will be recruited. They will be randomly divided into an experimental group (n = 17) photobiomodulation (808nm, 100 mW, and 4J/cm2 with 5 points per vestibular). Applications will be made in the immediate postoperative period and 24 hours after surgery. Control group (n = 17) a FBM simulation will be performed in the same way as in the experimental group. In this group, the required analgesia will be administered within the standard with ibuprofen. Both groups will perform the necessary conventional procedures considered the gold standard in the literature. Both the patient and the evaluator will be blinded to the intervention performed. The primary outcome variable of the study will be postoperative pain, which will be assessed using the visual analog scale at all postoperative control visits (baseline, 24 hours and 7 days). As for the secondary outcome variables, the amount of systemic medication received according to the patient's need (will be provided by the investigator).. Radiographic images will be obtained after 1 and 2 months for evaluation of the repair (dimensions of the lesion, radiopacity). These radiographs will be taken digitally with the positioners implemented. Edema, ecchymosis, and evaluation of soft tissues in the anterior portion of the intra and extra-oral maxilla will also be evaluated. In addition, a digital thermometer. These parameters will be evaluated 24 hours and 7 days after the intervention. The X-rays will be taken in the 1st and 3rd month respectively.

Description:

Photobiomodulation (FBM) has shown favorable results in the postoperative period of endodontic surgery, however, up to now, the level of evidence in this procedure is low. The objective of this study will be to evaluate if photobiomodulation (FBM) can reduce postoperative pain in patients who will undergo endodontic surgery. For this randomized, controlled, and double-blind clinical study, 34 Uruguayan participants of both sexes who previously consulted at the Clínica Universitaria de la Salud, with a diagnosis of periodontitis with an apical lesion less than 10mm with or without a fistula, diagnosed clinically and radiographically, in the upper maxillary region (from 15 to 25) will be recruited. Participants included in the study must have periapical lesions who have already undergone endodontic treatment (lesions smaller than 10mm in their greatest diameter - Metin et al., 2018, single and chronic lesions), no comorbidities, age from 18 to 70 years, both genders, healthy permanent teeth with good hygiene. Participants will be excluded if they are taking drugs that affect bone metabolism and the inflammatory process (for example corticosteroids, bisphosphonates), Smokers, pregnant or lactating women, if used anti-inflammatory drugs in the last 3 months before surgery, who do not follow the guidelines or have an injury in the acute phase (pain, edema, exudate). They will be randomly divided into an experimental group (n = 17) photobiomodulation (808nm, 100 mW, and 4J/cm2 with 5 points per vestibular). Applications will be made in the immediate postoperative period and 24 hours after surgery. Control group (n = 17) FBM simulation will be performed in the same way as in the experimental group. In this group, the required analgesia will be administered within the standard with ibuprofen. Both groups will perform the necessary conventional procedures considered the gold standard in the literature. Both the patient and the evaluator will be blinded to the intervention performed. The primary outcome variable of the study will be postoperative pain, which will be assessed using the visual analog scale at all postoperative control visits (baseline, 24 hours, and 7 days). As for the secondary outcome variables, the amount of systemic medication received according to the patient's need (will be provided by the investigator). Radiographic images will be obtained after 1 and 3 months for evaluation of the repair (dimensions of the lesion, radiopacity). These radiographs will be taken digitally with the positioners implemented. Edema, ecchymosis, and evaluation of soft tissues in the anterior portion of the intra and extra-oral maxilla will also be evaluated. In addition, the temperature with a digital thermometer. These parameters will be evaluated 24 hours and 7 days after the intervention. The X-rays will be taken in the 1st and 3rd months, respectively. Once all the data have been collected, their normality will be tested, and the one-way ANOVA test and the complementary Tukey test will be carried out. Data will be presented as mean ± standard deviation (SD) and the accepted p-value will be <0.0

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 34
• Est. completion date: November 1, 2024
• Est. primary completion date: August 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria

:• Patients with periapical lesions who have already undergone endodontic treatment (lesions smaller than 10mm in their greatest diameter - Metin et al., 2018, single and chronic lesions)

• Patients with not comorbidities,

• Age from 18 to 70 years,

• Both genders,

• Healthy permanent teeth with good hygiene.

Exclusion Criteria:

• Who are taking drugs that affect bone metabolism and the inflammatory process (for example: corticosteroids, bisphosphonates),

• Smokers, pregnant or lactating women,

• Who used anti-inflammatory drugs in the last 3 months before surgery.

• Who for any reason interrupted the evolution of the treatment for not attending joint appointments.

• Patients who do not follow the guidelines or have an injury in the acute phase (pain, edema, exudate)

Related Conditions & MeSH terms

• Dental Pulp Diseases
• Endodontic Disease
• Inflammation
• Pain
• Pain, Postoperative
• Photobiomodulation
• Surgery

Intervention

Drug:
• Ibuprofen
All participants will undergo the same conventional surgical procedure. Patients will receive the FBM simulation and will be treated identically to the G2 group.

Other:
• Photobiomodulation simulation
The person responsible for applying the FBM will simulate the radiation by placing the devices in the same places described for the FBM group, however, the equipment will remain turned off.

Device:
• Photobiomodulation
. Patients will receive FBM and will be treated identically to the G2 group. The irradiated region will be on the lesion at 4 equidistant points on the vertex of a flat square 1 cm away.

Other:
• Ibuprofen simulation
Placebo ibuprofen will be manipulated by pharmacy (Matias Gonzalez)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Nove de Julho

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain in postoperative period - baseline	Pain will be measured during the immediate postoperative period of endodontic surgery using the Visual Analogue Scale (VAS) measured in millimeters, where "0" is no pain and "10" is the worst pain in life (Metin et al. ., 2018, Sampaio-Filho et al., 2018).	at baseline
Primary	Pain in postoperative period - 24 hours after treatment	Pain will be measured at 24hours of postoperative period of endodontic surgery using the Visual Analogue Scale (VAS) measured in millimeters, where "0" is no pain and "10" is the worst pain in life (Metin et al. ., 2018, Sampaio-Filho et al., 2018).	24 hours after treatment
Primary	Pain in postoperative period -7 days after treatment	Pain will be measured at 7d of postoperative period of endodontic surgery using the Visual Analogue Scale (VAS) measured in millimeters, where "0" is no pain and "10" is the worst pain in life (Metin et al., 2018, Sampaio-Filho et al., 2018).	7 days after treatment
Secondary	Quantity of painkillers ingested in the period - baseline	the number of painkillers ingested will be counted. The analgesic used will be only paracetamol that will be administered to the patient, but it is advisable to take it only in case of pain (Sampaio-Filho et al., 2018). A procedure will be carried out to monitor the adherence of the participants (for example, each patient will be asked to bring the pain reliever pack to the appointment to see how it is used).	at baseline
Secondary	Quantity of painkillers ingested in the period - 24 hours after treatment	the quantity of painkillers ingested in the 24-hours will be counted. The analgesic used will be only paracetamol that will be administered to the patient, but it is advisable to take it only in case of pain (Sampaio-Filho et al., 2018). A procedure will be carried out to monitor the adherence of the participants (for example, each patient will be asked to bring the pain reliever pack to the appointment to see how it is used).	24 hours after treatment
Secondary	Quantity of painkillers ingested in the period - 7 days after treatment	the number of painkillers ingested in the 7-day period will be counted. The analgesic used will be only paracetamol that will be administered to the patient, but it is advisable to take it only in case of pain (Sampaio-Filho et al., 2018). A procedure will be carried out to monitor the adherence of the participants (for example, each patient will be asked to bring the pain reliever pack to the appointment to see how it is used).	7 days after treatment
Secondary	Edema - baseline	A scale will be used to quantify the amount of edema as recommended by some authors (Metin et al., 2018). The scale is made up of scores from 0 to 3, where: 0 = no edema, 1 = intraoral edema, 2 = extraoral edema, 3 = diffuse edema (Metin et al., 2018).	at baseline
Secondary	Edema - 24 hours after treatment	A scale will be used to quantify the amount of edema as recommended by some authors (Metin et al., 2018). The scale is made up of scores from 0 to 3, where: 0 = no edema, 1 = intraoral edema, 2 = extraoral edema, 3 = diffuse edema (Metin et al., 2018).	24 hours after treatment
Secondary	Edema - 7 days after treatment	A scale will be used to quantify the amount of edema as recommended by some authors (Metin et al., 2018). The scale is made up of scores from 0 to 3, where: 0 = no edema, 1 = intraoral edema, 2 = extraoral edema, 3 = diffuse edema (Metin et al., 2018).	7 days after treatment
Secondary	Ecchymosis - baseline	is bleeding in the subcutaneous tissue, with a diameter greater than 1 cm, which is caused by the rupture of one or more blood capillaries and one of the causes is surgical trauma. Ecchymosis: 0 = no color change, 1 = spot smaller than 4 cm in diameter, 2 = spot 4-10 cm in diameter, 3 = spot larger than 10 cm in diameter (Metin et al., 2018).	at baseline
Secondary	Ecchymosis - 24 hours after treatment	is bleeding in the subcutaneous tissue, with a diameter greater than 1 cm, which is caused by the rupture of one or more blood capillaries and one of the causes is surgical trauma. Ecchymosis: 0 = no color change, 1 = spot smaller than 4 cm in diameter, 2 = spot 4-10 cm in diameter, 3 = spot larger than 10 cm in diameter (Metin et al., 2018).	24 hours after treatment
Secondary	Ecchymosis -7 days after treatment	is bleeding in the subcutaneous tissue, with a diameter greater than 1 cm, which is caused by the rupture of one or more blood capillaries and one of the causes is surgical trauma. Ecchymosis: 0 = no color change, 1 = spot smaller than 4 cm in diameter, 2 = spot 4-10 cm in diameter, 3 = spot larger than 10 cm in diameter (Metin et al., 2018).	7 days after treatment
Secondary	Soft tissue healing - baseline	Score 1: no opening at the incision line, no drainage (pus or exudate), no inflammation, no pain. Score 2: no opening at the incision line, no drainage, mild swelling, mild pain. Score 3: no opening at the incision line, active drainage, advanced inflammation, moderate to advanced pain. Score 4: opening at the incision line, active drainage, advanced inflammation, ongoing pain.	at baseline
Secondary	Soft tissue healing - 24 hours after treatment	Score 1: no opening at the incision line, no drainage (pus or exudate), no inflammation, no pain. Score 2: no opening at the incision line, no drainage, mild swelling, mild pain. Score 3: no opening at the incision line, active drainage, advanced inflammation, moderate to advanced pain. Score 4: opening at the incision line, active drainage, advanced inflammation, ongoing pain.	24 hours after treatment
Secondary	Soft tissue healing -7 days after treatment	Score 1: no opening at the incision line, no drainage (pus or exudate), no inflammation, no pain. Score 2: no opening at the incision line, no drainage, mild swelling, mild pain. Score 3: no opening at the incision line, active drainage, advanced inflammation, moderate to advanced pain. Score 4: opening at the incision line, active drainage, advanced inflammation, ongoing pain.	7 days after treatment
Secondary	Bone consolidation - baseline	Periapical radiography will evaluate the changes in the area of the defect (bone density). Periapical radiographs will always be performed with the same equipment using the parallelism technique. The area of the defect will be measured by multiplying the longest mesiodistal and supero-inferior diameters on the radiographs. In all radiographs, the longest diameter of the lesion was measured and the periapical index was evaluated. The periapical index was recorded according to the following parameters: 0 = no lesion, 1 = periapical radiolucency with a diameter of 0.5-1 mm, 2 = periapical radiolucency with a diameter of 1.1-2 mm, 3 = radiolucency periapical with a diameter of 2.1-4 mm, 4 = periapical radiolucency with a diameter of 4.1-8 mm and 5 = periapical radiolucency greater than 8.1 mm in diameter.	at baseline
Secondary	Bone consolidation - 24 hours after treatment	Periapical radiography will evaluate the changes in the area of the defect (bone density). Periapical radiographs will always be performed with the same equipment using the parallelism technique. The area of the defect will be measured by multiplying the longest mesiodistal and supero-inferior diameters on the radiographs. In all radiographs, the longest diameter of the lesion was measured and the periapical index was evaluated. The periapical index was recorded according to the following parameters: 0 = no lesion, 1 = periapical radiolucency with a diameter of 0.5-1 mm, 2 = periapical radiolucency with a diameter of 1.1-2 mm, 3 = radiolucency periapical with a diameter of 2.1-4 mm, 4 = periapical radiolucency with a diameter of 4.1-8 mm and 5 = periapical radiolucency greater than 8.1 mm in diameter.	24 hours after treatment
Secondary	Bone consolidation - 7 days after treatment	Periapical radiography will evaluate the changes in the area of the defect (bone density). Periapical radiographs will always be performed with the same equipment using the parallelism technique. The area of the defect will be measured by multiplying the longest mesiodistal and supero-inferior diameters on the radiographs. In all radiographs, the longest diameter of the lesion was measured and the periapical index was evaluated. The periapical index was recorded according to the following parameters: 0 = no lesion, 1 = periapical radiolucency with a diameter of 0.5-1 mm, 2 = periapical radiolucency with a diameter of 1.1-2 mm, 3 = radiolucency periapical with a diameter of 2.1-4 mm, 4 = periapical radiolucency with a diameter of 4.1-8 mm and 5 = periapical radiolucency greater than 8.1 mm in diameter.	7 days after treatment